Surgical cytoreduction versus systemic therapy in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms (GEP-NENS): a national cancer database analysis (NCDB)
Surgical cytoreduction was associated with significantly improved survival compared with systemic therapy alone in metastatic GEP-NENs, with consistent benefits across histologic grades and primary tumor sites. These findings support considering CRS in appropriately selected patients and underscore the need for prospective validation.
Authors
- Madison Conces (ORCID: https://orcid.org/0000-0003-1505-0521)
- Melissa Lumish (ORCID: https://orcid.org/0000-0003-4173-5567)
- Lauren E. Henke (ORCID: https://orcid.org/0000-0003-2208-3241)
- Asem A. Mohamed (ORCID: https://orcid.org/0000-0002-9083-576X)
- Fasih Ali Ahmed (ORCID: https://orcid.org/0000-0002-6648-5237)
- Richard S. Hoehn (ORCID: https://orcid.org/0000-0003-1455-6758)
- Trisha Lal (ORCID: https://orcid.org/0009-0000-5821-1159)
- John B. Ammori (ORCID: https://orcid.org/0000-0003-2131-0369)
- D. Bajor
- Sakti Chakrabarti (ORCID: https://orcid.org/0000-0002-1582-098X)
- Omkar Pawar (ORCID: https://orcid.org/0009-0006-1086-0911)
- Jeffrey M. Hardacre
- Sylvia Asa
- Eva Selfridge
- Amit Mahipal
- Jordan Winter
- Sree Tirumani
Institutions
- University Hospitals Seidman Cancer Center (US)
- Stanford University (US)
Publication Details
- Journal
- Oncology Reviews
- Published
- 2026-01-14
- DOI
- https://doi.org/10.3389/or.2025.1589775
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.00